earnings before interest, tax, depreciation and amortization (EBITDA) from operation pursuant Consolidated Financial Statements in the amount of THB 81 million decreased by THB 13 million or 14.1 percent

. DOD017/2562 May 8, 2019 Re: Management’s Discussion and Analysis (MD&A) of the Consolidated Financial Results for Quarter 1 of 2019 To: The President The Stock Exchange of Thailand DOD Biotech Public

regard, the company would like to report operating results for the second quarter of 2020 as follows Consolidated Financial Statements Ekachai Medical Care Public Company Limited and its subsidiaries

31, 2018 which is differenced more than 20% compare from previous financial year same quarter as follows: 1. The company consolidated revenues from sales and services for this period increase from

of Finansia Syrus Securities Public Company Limited (the“Company”) and its subsidiary for the six months period ended June 30th, 2017. The Consolidated net profit of the Company was Baht 92.65 million

Company Limited and its subsidiaries (“the Company”) would like to clarify herewith the operating result for the year 2017 as follows:- Financial Position As at 31 December 2017, total consolidated assets

is differenced more than 20% compare from previous financial year same quarter as follows: 1. The company consolidated revenues from sales and services for this period increase from 66.01 MB to 76.20

Company Q3 30/09/2020       2020 Reviewed Consolidated Q3 30/09/2020       2019   Company Year 31/12/2019       2019   Consolidated Year 31/12/2019       Last updated on 31 March 2022

is differenced more than 20% compare from previous financial year same quarter as follows: 1. The company consolidated revenues from sales and services for this period increase from 76.21 MB to 159.22

Reviewed Company Q3 30/09/2022       2022 Reviewed Consolidated Q3 30/09/2022       2021   Company Year 31/12/2021       2021   Consolidated Year 31/12/2021       Last updated on 19 January 2023